Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 93

1.

The dark side of stem cells: triggering cancer progression by cell fusion.

Dittmar T, Nagler C, Niggemann B, Zänker KS.

Curr Mol Med. 2013 Jun;13(5):735-50. Review.

PMID:
23642055
2.

Recurrence cancer stem cells--made by cell fusion?

Dittmar T, Nagler C, Schwitalla S, Reith G, Niggemann B, Zänker KS.

Med Hypotheses. 2009 Oct;73(4):542-7. doi: 10.1016/j.mehy.2009.05.044. Epub 2009 Jun 28.

PMID:
19564079
3.

Cell fusion is a potent inducer of aneuploidy and drug resistance in tumor cell/ normal cell hybrids.

Berndt B, Zänker KS, Dittmar T.

Crit Rev Oncog. 2013;18(1-2):97-113. Review.

PMID:
23237554
4.

Cell Fusion, Drug Resistance and Recurrence CSCs.

Nagler C, Zänker KS, Dittmar T.

Adv Exp Med Biol. 2011;714:173-82. doi: 10.1007/978-94-007-0782-5_9. Review.

PMID:
21506014
5.

Tumor-associated macrophages regulate tumorigenicity and anticancer drug responses of cancer stem/initiating cells.

Jinushi M, Chiba S, Yoshiyama H, Masutomi K, Kinoshita I, Dosaka-Akita H, Yagita H, Takaoka A, Tahara H.

Proc Natl Acad Sci U S A. 2011 Jul 26;108(30):12425-30. doi: 10.1073/pnas.1106645108. Epub 2011 Jul 11.

6.
7.

Tumor associated macrophage × cancer cell hybrids may acquire cancer stem cell properties in breast cancer.

Ding J, Jin W, Chen C, Shao Z, Wu J.

PLoS One. 2012;7(7):e41942. doi: 10.1371/journal.pone.0041942. Epub 2012 Jul 25.

8.

Carcinogenesis driven by bone marrow-derived stem cells.

Dittmar T, Seidel J, Zaenker KS, Niggemann B.

Contrib Microbiol. 2006;13:156-69. Review.

PMID:
16627964
9.

Tumor initiating cells.

Bansal N, Banerjee D.

Curr Pharm Biotechnol. 2009 Feb;10(2):192-6. Review.

PMID:
19199951
10.

Research progress in cancer stem cells and their drug resistance.

Yu H, Zhang CM, Wu YS.

Chin J Cancer. 2010 Mar;29(3):261-4. Review.

11.

Accessories to the crime: functions of cells recruited to the tumor microenvironment.

Hanahan D, Coussens LM.

Cancer Cell. 2012 Mar 20;21(3):309-22. doi: 10.1016/j.ccr.2012.02.022. Review.

12.

The origin of cancer stem cells.

Bu Y, Cao D.

Front Biosci (Schol Ed). 2012 Jan 1;4:819-30. Review.

PMID:
22202093
13.

Co-opting macrophage traits in cancer progression: a consequence of tumor cell fusion?

Pawelek J, Chakraborty A, Lazova R, Yilmaz Y, Cooper D, Brash D, Handerson T.

Contrib Microbiol. 2006;13:138-55. Review.

PMID:
16627963
14.

Tumour macrophages as potential targets of bisphosphonates.

Rogers TL, Holen I.

J Transl Med. 2011 Oct 17;9:177. doi: 10.1186/1479-5876-9-177. Review.

15.

Stem cells, melanoma and cancer stem cells: the good, the bad and the evil?

Menaa F, Houben R, Eyrich M, Broecker EB, Becker JC, Wischhusen J.

G Ital Dermatol Venereol. 2009 Jun;144(3):287-96. Epub 2008 Dec 17. Review.

PMID:
19088701
16.

Pancreatic cancer stem cells.

Lee CJ, Dosch J, Simeone DM.

J Clin Oncol. 2008 Jun 10;26(17):2806-12. doi: 10.1200/JCO.2008.16.6702. Review.

PMID:
18539958
17.

[Tumor dormancy and identification of therapeutic targets].

Li CF, Cao S, Meng SD.

Ai Zheng. 2009 May;28(5):555-8. Review. Chinese.

PMID:
19624889
18.

Cancer (stem) cell differentiation: An inherent or acquired property?

Mohr M, Zänker KS, Dittmar T.

Med Hypotheses. 2015 Dec;85(6):1012-8. doi: 10.1016/j.mehy.2015.08.017. Epub 2015 Sep 4.

PMID:
26347071
19.

Molecular aspects of cancer cell resistance to chemotherapy.

Rebucci M, Michiels C.

Biochem Pharmacol. 2013 May 1;85(9):1219-26. doi: 10.1016/j.bcp.2013.02.017. Epub 2013 Feb 19. Review.

PMID:
23435357
20.

Fusion-derived epithelial cancer cells express hematopoietic markers and contribute to stem cell and migratory phenotype in ovarian carcinoma.

Ramakrishnan M, Mathur SR, Mukhopadhyay A.

Cancer Res. 2013 Sep 1;73(17):5360-70. doi: 10.1158/0008-5472.CAN-13-0896. Epub 2013 Jul 15.

Supplemental Content

Support Center